Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revumenib + FLA in NUP98-rearranged AML
NCT07686107Phase 2Not yet recruiting
- Sponsor
- Therapeutic Advances in Childhood Leukemia and Lymphoma Consortium
- Start
- Aug 2026
- Primary completion
- Dec 2029
01
Overview
A Phase 2 trial of revumenib in acute myeloid leukemia (AML), sponsored by Therapeutic Advances in Childhood Leukemia and Lymphoma Consortium. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
revumenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07686107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07686107.